WHO urges nations to closely monitor adverse effects of any vaccine in use

All countries should closely monitor adverse health effects related to the use of any vaccine, a spokesperson for the World Health Organization (WHO) said

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
Representative Image
ANI Europe
2 min read Last Updated : Mar 12 2021 | 9:04 AM IST

All countries should closely monitor adverse health effects related to the use of any vaccine, a spokesperson for the World Health Organization (WHO) told Sputnik following the suspension of the AstraZeneca drug in several EU countries.

A number of European states have suspended vaccination with the AstraZeneca drug as a precaution after reports on severe side-effects, including blood clots, that were allegedly triggered by the vaccine. The European Medicines Agency said there was currently no indication that the reported negative effects had been caused by the vaccination.

"WHO encourages all countries to continue to carefully monitor for any adverse events following immunization (AEFIs) with any vaccine and to report any serious cases of AEFIs to the global AEFI surveillance database," the spokesperson said on late Thursday.

The WHO's Global Advisory Committee on Vaccine Safety (GACVS) reviews all the reports on the vaccines' safety, according to the organization's representative.

"WHO's Global Advisory Committee on Vaccine Safety (GACVS) systematically reviews any vaccine safety signals and concerns related to COVID-19 vaccine safety, to advise WHO on any new safety signals or concerns related to COVID-19 vaccines," the spokesperson said.

The World Health Organization declared the COVID-19 outbreak a pandemic on March 11, 2020. To date, more than 118.34 million people have been infected with the coronavirus worldwide, with over 2.62 million fatalities, according to Johns Hopkins University.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :World Health OrganisationWHOCoronavirus Vaccine

First Published: Mar 12 2021 | 9:00 AM IST

Next Story